Genzyme, a Sanofi Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Genzyme, a Sanofi Company sits in the top decile of US sponsors by registered trial count (#154 of 15,742 sponsors by registered trial count).
Genzyme, a Sanofi Company: 196 sponsored US clinical trials, 4 recruiting.
Genzyme, a Sanofi Company sponsors 196 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 159 completed. 65 of these trials are in Phase 3-4 (later-stage) and 114 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glycogen Storage Disease Type II (GSD-II), with 5 trials.
Top-decile sponsor footprint
Genzyme, a Sanofi Company ranks in the top decile of sponsors by registered trial count (#154 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
159 of 188 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
196 total, page 3 of 4
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
NCT00295763
Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma
NCT00308087
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
NCT00315705
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
NCT00444912
A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.
NCT00293163
Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
NCT00445302
Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
NCT00268957
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
NCT00295165
A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus
NCT00361101
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
NCT00396331
A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease
NCT00158600
Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
NCT00244257
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
NCT00123461
Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT00125385
Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602
NCT00125879
Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone
NCT00137891
Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease
NCT00113035
Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
NCT00206726
Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection
NCT00117689
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
NCT00395967
Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
NCT00440648
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea
NCT00106509
Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication
NCT00117650
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
NCT00103610
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
NCT00103662
Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease
NCT00206661
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
NCT00098345
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease
NCT00074932
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
NCT00396201
A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease
NCT00229736
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation
NCT00396383
Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee
NCT00139295
A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients
NCT00144768
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
NCT00086580
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim
NCT00206713
Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients
NCT00322387
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
NCT00088543
Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
NCT00322491
Trilostane for Androgen-Independent Prostate Cancer
NCT00181597
A Prospective, Observational Study in Patients With Late-Onset Pompe Disease
NCT00077662
A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care
NCT00081900
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00071188
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00081497
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
NCT00078455
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
NCT00113048
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
NCT00077961
Mucopolysaccharidosis I (MPS I) Registry
NCT00144794
A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip
NCT00131326
Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors
NCT00125827
Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
NCT00069862
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 66 |
| Phase 3 | 40 |
| Phase 4 | 25 |
Therapeutic Areas
What is open in the Genzyme, a Sanofi Company pipeline
4 recruiting of 196 indexed (2% open); 159 completed (81%).
Phase mix: 65 late (III/IV) vs 114 early (I/II) (early-phase heavy).
Top condition: Glycogen Storage Disease Type II (GSD-II) (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Genzyme, a Sanofi Company: open-pipeline peers nationwide
Peers matched on 196 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Genzyme, a Sanofi Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 196 trials (± recruiting share)
- Hospital for Special Surgery, New York · 194 trials · 18% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
- National Center for Complementary and Integrative Health (NCCIH) · 203 trials · 3% recruiting
- The University of Texas Medical Branch, Galveston · 203 trials · 14% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Cynosure · 2% recruiting · 49 trials
- Carelon Research · 2% recruiting · 50 trials
- Sun Pharmaceutical Industries · 2% recruiting · 48 trials
- Sanofi Pasteur, a Sanofi Company · 2% recruiting · 153 trials
Related
What to do with this Genzyme, a Sanofi Company page
196 registered trials is a research-attention snapshot, not an endorsement of Genzyme, a Sanofi Company or any single study.
- 4 of Genzyme, a Sanofi Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Glycogen Storage Disease Type II (GSD-II) is the condition Genzyme, a Sanofi Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glycogen Storage Disease Type II (GSD-II) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Genzyme, a Sanofi Company pipeline card: 196 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.